Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines

BACKGROUND: Temsirolimus is a mammalian target of rapamycin (mTOR) inhibitor and rapamycin analogue that is approved for treating advanced renal cell carcinoma (RCC). It is being actively evaluated in clinical trials for melanoma. The mTOR inhibitors are also immunosuppressants and are used clinical...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Wang, Y, Wang, X-Y, Subjeck, J R, Shrikant, P A, Kim, H L
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2011
Sujets:
Translational Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3049595/
https://ncbi.nlm.nih.gov/pubmed/21285988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.15
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires